Working… Menu

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02383927
Recruitment Status : Active, not recruiting
First Posted : March 10, 2015
Last Update Posted : June 23, 2020
Information provided by (Responsible Party):
Kura Oncology, Inc.